Management of CMV in HSCT Recipients

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

CMV: A Common Infection After HSCT

CMV: Most Clinically Significant Viral Infection in HSCT Recipients in the Era of Preemptive Therapy

Risk Factors for CMV Reactivation

CMV Serostatus: A Key Consideration in High-Risk Patients

CMV Management Strategies

Preemptive Therapy: Unmet Needs

CMV Prevention in HSCT Recipients: What's in the Pipeline?

Primary Letermovir Prophylaxis in High-Risk Patients

Primary Letermovir Prophylaxis in High-Risk Patients (cont)

SUPPRESS Primary Brincidofovir Prophylaxis in High-Risk Patients

Brincidofovir: The AdVise Trial Treatment of Adenovirus

Maribavir Treatment of Resistant/Refractory Infections in HSCT and SOT Recipients

Adoptive T-Cell Transfer Restoring Cellular Immunity in the Recipient

CMV Vaccines: The Future of CMV Prevention?

Anti-CMV Combination mAb Restoring Humoral Immunity in the Recipient

Concluding Remarks

Abbreviations